nach oben

Erschienen in:

01.06.2012 | Clinical and Epidemiological Study

Genotypic resistance profiles associated with virological failure to darunavir-containing regimens: a cross-sectional analysis

verfasst von: G. Sterrantino, M. Zaccarelli, G. Colao, F. Baldanti, S. Di Giambenedetto, T. Carli, F. Maggiolo, M. Zazzi, For the ARCA Database Study Group

Erschienen in: Infection | Ausgabe 3/2012

Einloggen, um Zugang zu erhalten

Abstract

Introduction

This study aimed at defining protease (PR) resistance mutations associated with darunavir (DRV) failure and PR resistance evolution at DRV failure in a large database of treatment-experienced human immunodeficiency virus (HIV) patients.

Results

Overall, 1,104 patients were included: 118 (10.7%) failed at a median observation time of 16 months. The mean number of PR mutations at baseline was 2.7, but it was higher in patients who subsequently failed DRV. In addition, the number of PR mutations increased at failure. The increase in the mean number of mutations was completely related to mutations considered to be associated with DRV resistance following the indications of the main DRV clinical trials.

Discussion

The higher statistical difference at baseline between failing versus non-failing patients was observed for the V32I and I84V mutations. At DRV failure, the major increase was still observed for V32I; I54L, V11I, T74P and I50V also increased. Despite the increment in the mean number of mutations per patient between baseline and failure, in 21 patients (17.8%) at baseline and 36 (30.5%) at failure, no PR mutation was detected.

Conclusion

The HIV-DB interpretation algorithm identified few patients with full DRV resistance at baseline and few patients developed full resistance at DRV failure, indicating that complete resistance to DRV is uncommon.

Nur mit Berechtigung zugänglich

De Meyer S, Azijn H, Surleraux D, Jochmans D, Tahri A, Pauwels R, Wigerinck P, de Béthune MP. TMC114, a novel human immunodeficiency virus type 1 protease inhibitor active against protease inhibitor-resistant viruses, including a broad range of clinical isolates. Antimicrob Agents Chemother. 2005;49:2314–21.PubMedCrossRef

Lefebvre E, Schiffer CA. Resilience to resistance of HIV-1 protease inhibitors: profile of darunavir. AIDS Rev. 2008;10:131–42.PubMed

Dierynck I, De Wit M, Gustin E, Keuleers I, Vandersmissen J, Hallenberger S, Hertogs K. Binding kinetics of darunavir to human immunodeficiency virus type 1 protease explain the potent antiviral activity and high genetic barrier. J Virol. 2007;81:13845–51.PubMedCrossRef

Koh Y, Nakata H, Maeda K, Ogata H, Bilcer G, Devasamudram T, Kincaid JF, Boross P, Wang YF, Tie Y, Volarath P, Gaddis L, Harrison RW, Weber IT, Ghosh AK, Mitsuya H. Novel bis-tetrahydrofuranylurethane-containing nonpeptidic protease inhibitor (PI) UIC-94017 (TMC114) with potent activity against multi-PI-resistant human immunodeficiency virus in vitro. Antimicrob Agents Chemother. 2003;47:3123–9.PubMedCrossRef

Tie Y, Boross PI, Wang YF, Gaddis L, Hussain AK, Leshchenko S, Ghosh AK, Louis JM, Harrison RW, Weber IT. High resolution crystal structures of HIV-1 protease with a potent non-peptide inhibitor (UIC-94017) active against multi-drug-resistant clinical strains. J Mol Biol. 2004;338:341–52.PubMedCrossRef

King NM, Prabu-Jeyabalan M, Nalivaika EA, Schiffer CA. Combating susceptibility to drug resistance: lessons from HIV-1 protease. Chem Biol. 2004;11:1333–8.PubMed

Surleraux DL, Tahri A, Verschueren WG, Pille GM, de Kock HA, Jonckers TH, Peeters A, De Meyer S, Azijn H, Pauwels R, de Bethune MP, King NM, Prabu-Jeyabalan M, Schiffer CA, Wigerinck PB. Discovery and selection of TMC114, a next generation HIV-1 protease inhibitor. J Med Chem. 2005;48:1813–22.PubMedCrossRef

Santoro MM, Bertoli A, Lorenzini P, Ceccherini-Silberstein F, Gianotti N, Mussini C, Torti C, Di Perri G, Barbarini G, Bini T, Melzi S, Caramello P, Maserati R, Narciso P, Micheli V, Antinori A, Perno CF; CARe Study Group. Two different patterns of mutations are involved in the genotypic resistance score for atazanavir boosted versus unboosted by ritonavir in multiple failing patients. Infection. 2009;37:233–43.PubMed

McKeage K, Perry CM, Keam SJ. Darunavir: a review of its use in the management of HIV infection in adults. Drugs. 2009;69:477–503.PubMedCrossRef

10.

Mills AM, Nelson M, Jayaweera D, Ruxrungtham K, Cassetti I, Girard PM, Workman C, Dierynck I, Sekar V, Abeele CV, Lavreys L. Once-daily darunavir/ritonavir vs. lopinavir/ritonavir in treatment-naive, HIV-1-infected patients: 96-week analysis. AIDS. 2009;23:1679–88.PubMedCrossRef

11.

De Meyer S, Lathouwers E, Dierynck I, De Paepe E, Van Baelen B, Vangeneugden T, Spinosa-Guzman S, Lefebvre E, Picchio G, de Béthune MP. Characterization of virologic failure patients on darunavir/ritonavir in treatment-experienced patients. AIDS. 2009;23:1829–40.PubMedCrossRef

12.

Clotet B, Bellos N, Molina JM, Cooper D, Goffard JC, Lazzarin A, Wöhrmann A, Katlama C, Wilkin T, Haubrich R, Cohen C, Farthing C, Jayaweera D, Markowitz M, Ruane P, Spinosa-Guzman S, Lefebvre E; POWER 1 and 2 study groups. Efficacy and safety of darunavir–ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials. Lancet. 2007;369:1169–78.PubMedCrossRef

13.

De Meyer S, Hill A, De Baere I, Rimsky L, Azijn H, Van Baelen B, De Paepe E, Vangeneugden T, Lefebvre E, De Béthune MP. Effect of baseline susceptibility and on-treatment mutations on TMC114 and control PI efficacy. In: Proceedings of the 13th Conference on Retroviruses and Opportunistic Infections (CROI 2006), Denver, CO, USA, 5–8 February 2006 Abstract 157.

14.

Llibre JM, Puig T, Liu TF, Martinez-Picado J, Santos JR, Bravo I, Shafer RW, Schapiro JM, Clotet B. Predicted resistance to tipranavir and darunavir in clinical samples from 1999–2006 with protease resistance mutations. In: Proceedings of the 11th European AIDS Conference/EACS, Madrid, Spain, 24–27 October 2007. Abstract P3.4/05.

15.

Descamps D, Lambert-Niclot S, Marcelin AG, Peytavin G, Roquebert B, Katlama C, Yeni P, Felices M, Calvez V, Brun-Vézinet F. Mutations associated with virological response to darunavir/ritonavir in HIV-1-infected protease inhibitor-experienced patients. J Antimicrob Chemother. 2009;63:585–92.PubMedCrossRef

16.

Moltó J, Santos JR, Pérez-Alvarez N, Cedeño S, Miranda C, Khoo S, Else L, Llibre JM, Valle M, Clotet B. Darunavir inhibitory quotient predicts the 48-week virological response to darunavir-based salvage therapy in human immunodeficiency virus-infected protease inhibitor-experienced patients. Antimicrob Agents Chemother. 2008;52:3928–32.PubMedCrossRef

17.

Delaugerre C, Mathez D, Peytavin G, Berthé H, Long K, Galperine T, de Truchis P. Key amprenavir resistance mutations counteract dramatic efficacy of darunavir in highly experienced patients. AIDS. 2007;21:1210–3.PubMedCrossRef

18.

Molina JM, Cohen C, Katlama C, Grinsztejn B, Timerman A, Pedro Rde J, Vangeneugden T, Miralles D, Meyer SD, Parys W, Lefebvre E; TMC114-C208 Study Group; TMC114-C215 Study Group. Safety and efficacy of darunavir (TMC114) with low-dose ritonavir in treatment-experienced patients: 24-week results of POWER 3. J Acquir Immune Defic Syndr. 2007;46:24–31.PubMed

19.

Madruga JV, Berger D, McMurchie M, Suter F, Banhegyi D, Ruxrungtham K, Norris D, Lefebvre E, de Béthune MP, Tomaka F, De Pauw M, Vangeneugden T, Spinosa-Guzman S; TITAN study group. Efficacy and safety of darunavir-ritonavir compared with that of lopinavir-ritonavir at 48 weeks in treatment-experienced, HIV-infected patients in TITAN: a randomised controlled phase III trial. Lancet. 2007;370:49–58.PubMedCrossRef

20.

Orkin C, DeJesus E, Khanlou H, Stoehr A, Supparatpinyo K, Van de Casteele T, Lathouwers E, Spinosa-Guzman S. ARTEMIS: 192-week efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naïve HIV-1-infected adults. In: Proceedings of the 10th International Congress on Drug Therapy in HIV Infection, Glasgow, UK, 7–11 November 2010. J Int AIDS Soc. 2010;13:P3.

21.

Charpentier C, Roquebert B, Colin C, Taburet AM, Fagard C, Katlama C, Molina JM, Jacomet C, Brun-Vézinet F, Chêne G, Yazdanpanah Y, Descamps D; ANRS 139 TRIO Trial study group. Resistance analyses in highly experienced patients failing raltegravir, etravirine and darunavir/ritonavir regimen. AIDS. 2010;24:2651–6.PubMedCrossRef

22.

Johnson VA, Brun-Vézinet F, Clotet B, Günthard HF, Kuritzkes DR, Pillay D, Schapiro JM, Richman DD. Update of the drug resistance mutations in HIV-1: December 2010. Top HIV Med. 2010;18:156–63.PubMed

23.

Young J, Scherrer AU, Günthard HF, Opravil M, Yerly S, Böni J, Rickenbach M, Fux CA, Cavassini M, Bernasconi E, Vernazza P, Hirschel B, Battegay M, Bucher HC; Swiss HIV Cohort Study. Efficacy, tolerability and risk factors for virological failure of darunavir-based therapy for treatment-experienced HIV-infected patients: the Swiss HIV Cohort Study. HIV Med. 2011;12:299–307.PubMedCrossRef

24.

Stanford University, HIV Drug Resistance Database. http://hivdb.stanford.edu/.

25.

Brun-Vézinet F, Costagliola D, Khaled MA, Calvez V, Clavel F, Clotet B, Haubrich R, Kempf D, King M, Kuritzkes D, Lanier R, Miller M, Miller V, Phillips A, Pillay D, Schapiro J, Scott J, Shafer R, Zazzi M, Zolopa A, DeGruttola V. Clinically validated genotype analysis: guiding principles and statistical concerns. Antivir Ther. 2004;9:465–78.PubMed

26.

de Meyer S, Vangeneugden T, van Baelen B, de Paepe E, van Marck H, Picchio G, Lefebvre E, de Béthune MP. Resistance profile of darunavir: combined 24-week results from the POWER trials. AIDS Res Hum Retroviruses. 2008;24:379–88.PubMedCrossRef

27.

Pellegrin I, Wittkop L, Joubert LM, Neau D, Bollens D, Bonarek M, Girard PM, Fleury H, Winters B, Saux MC, Pellegrin JL, Thiébaut R, Breilh D; ANRS Co3 Aquitaine Cohort. Virological response to darunavir/ritonavir-based regimens in antiretroviral-experienced patients (PREDIZISTA study). Antivir Ther. 2008;13:271–9.PubMed

28.

Lambert-Niclot S, Flandre P, Canestri A, Peytavin G, Blanc C, Agher R, Soulié C, Wirden M, Katlama C, Calvez V, Marcelin AG. Factors associated with the selection of mutations conferring resistance to protease inhibitors (PIs) in PI-experienced patients displaying treatment failure on darunavir. Antimicrob Agents Chemother. 2008;52:491–6.PubMedCrossRef

29.

De Meyer S, Dierynck I, Lathouwers E, Van Baelen B, Vangeneugden T, Spinosa-Guzman S, Peeters M, Picchio G, de Béthune MP. Phenotypic and genotypic determinants of resistance to darunavir: analysis of data from treatment-experienced patients in POWER 1, 2, 3 and DUET-1 and DUET-2. In: Proceedings of the XVIIth International HIV Drug Resistance Workshop, Sitges, Spain, 10–14 June 2008. Antivir Ther 2008;13(Suppl 3):A33 (abs 31).

30.

Delaugerre C, Pavie J, Palmer P, Ghosn J, Blanche S, Roudiere L, Dominguez S, Mortier E, Molina JM, de Truchis P. Pattern and impact of emerging resistance mutations in treatment experienced patients failing darunavir-containing regimen. AIDS. 2008;22:1809–13.PubMedCrossRef

31.

Fox ZV, Geretti AM, Kjaer J, Dragsted UB, Phillips AN, Gerstoft J, Staszewski S, Clotet B, von Wyl V, Lundgren JD. The ability of four genotypic interpretation systems to predict virological response to ritonavir-boosted protease inhibitors. AIDS. 2007;21:2033–42.PubMedCrossRef

32.

Garrido C, Poveda E, Corral A, de Mendoza C, Soriano V. Low rate of tipranavir and darunavir resistance mutations in PI-experienced patients using the new interpretation scores—implications for PI sequencing. In: Proceedings of the XVIIth International HIV Drug Resistance Workshop, Sitges, Spain, 10–14 June 2008. Antivir Ther 2008;13(Suppl 3):A107 (abs 97).

33.

Poveda E, de Mendoza C, Martin-Carbonero L, Corral A, Briz V, González-Lahoz J, Soriano V. Prevalence of darunavir resistance mutations in HIV-1-infected patients failing other protease inhibitors. J Antimicrob Chemother. 2007;60:885–8.PubMedCrossRef

34.

Talbot A, Grant P, Taylor J, Baril JG, Liu TF, Charest H, Brenner B, Roger M, Shafer R, Cantin R, Zolopa A. Predicting tipranavir and darunavir resistance using genotypic, phenotypic, and virtual phenotypic resistance patterns: an independent cohort analysis of clinical isolates highly resistant to all other protease inhibitors. Antimicrob Agents Chemother. 2010;54:2473–9.PubMedCrossRef

Titel: Genotypic resistance profiles associated with virological failure to darunavir-containing regimens: a cross-sectional analysis
verfasst von: G. Sterrantino
M. Zaccarelli
G. Colao
F. Baldanti
S. Di Giambenedetto
T. Carli
F. Maggiolo
M. Zazzi
For the ARCA Database Study Group
Publikationsdatum: 01.06.2012
Verlag: Springer-Verlag
Erschienen in: Infection / Ausgabe 3/2012
Print ISSN: 0300-8126
Elektronische ISSN: 1439-0973
DOI: https://doi.org/10.1007/s15010-011-0237-y

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Genotypic resistance profiles associated with virological failure to darunavir-containing regimens: a cross-sectional analysis